Skip to content

Lexicon Pharmaceuticals LXRX Net investment gains (losses)

Net investment gains (losses) at other companies

Opko Health logo
Opko HealthOPK
-$298K-9.2%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.75K+1,275%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$22.58M+1,321%

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's net investment gains (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's net investment gains (losses)?
Lexicon Pharmaceuticals (LXRX) reported net investment gains (losses) of $100K in Q1 2026.
What does net investment gains (losses) mean?
Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.